These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 485747)

  • 1. Therapy of primary amyloidosis with melphalan and prednisone.
    Schwartz RS; Cohen JR; Schrier SL
    Arch Intern Med; 1979 Oct; 139(10):1144-7. PubMed ID: 485747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
    Kyle RA; Gertz MA; Greipp PR; Witzig TE; Lust JA; Lacy MQ; Therneau TM
    N Engl J Med; 1997 Apr; 336(17):1202-7. PubMed ID: 9110907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.
    Kyle RA; Wagoner RD; Holley KE
    Arch Intern Med; 1982 Aug; 142(8):1445-7. PubMed ID: 7103624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.
    Benson MD
    Arthritis Rheum; 1986 May; 29(5):683-7. PubMed ID: 3718560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
    Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
    Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary amyloidosis associated to severe factor X deficiency].
    Pérez Martínez J; Llamas F; López Montes A; Massó P; Poblet E; López Rubio E; Gallego E; Gómez Roldán C
    Nefrologia; 2004; 24(5):493-8. PubMed ID: 15648909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cardiac amyloidosis with 20-year survival.
    Fealey ME; Edwards WD; Grogan M; Dispenzieri A
    Cardiovasc Pathol; 2006; 15(6):331-5. PubMed ID: 17113011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.
    Cohen HJ; Lessin LS; Hallal J; Burkholder P
    Ann Intern Med; 1975 Apr; 82(4):466-73. PubMed ID: 1119764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura.
    Patriarca F; Geromin A; Fanin R; Damiani D; Sperotto A; Baccarani M
    Bone Marrow Transplant; 1999 Aug; 24(4):433-5. PubMed ID: 10467336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.
    Skinner M; Anderson J; Simms R; Falk R; Wang M; Libbey C; Jones LA; Cohen AS
    Am J Med; 1996 Mar; 100(3):290-8. PubMed ID: 8629674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
    Sezer O; Schmid P; Shweigert M; Heider U; Eucker J; Harder H; Sinha P; Radtke H; Possinger K
    Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.
    Kyle RA; Greipp PR; Garton JP; Gertz MA
    Am J Med; 1985 Dec; 79(6):708-16. PubMed ID: 3934968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA; Sonneveld P; de Man RA; Leebeek FW
    Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine.
    Schattner A; Varon D; Green L; Hurwitz N; Bentwich Z
    Am J Med; 1989 Mar; 86(3):347-8. PubMed ID: 2919619
    [No Abstract]   [Full Text] [Related]  

  • 17. AL amyloidosis: therapeutic response in two patients with renal involvement.
    Goddard IR; Jackson R; Jones JM
    Nephrol Dial Transplant; 1991; 6(8):592-4. PubMed ID: 1956560
    [No Abstract]   [Full Text] [Related]  

  • 18. [Amyloidosis in a mixed pattern. Sensitivity to colchicine and melphalan].
    Frustaci A; Gentiloni N; Feoli F
    Minerva Med; 1981 Apr; 72(15):957-60. PubMed ID: 6784038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis.
    Mignot A; Bridoux F; Thierry A; Varnous S; Pujo M; Delcourt A; Gombert JM; Goujon JM; Favreau F; Touchard G; Herpin D; Jaccard A
    Haematologica; 2008 Mar; 93(3):e32-5. PubMed ID: 18310532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.